NCT00263783

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (planned)
• Sponsor: MedImmune LLC · Industry
• Sex: All
• Age: 18 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the safety profile of single and multiple doses of MEDI522 in patients with refractory solid tumors.

Conditions

• Cancer

Interventions

Type	Name	Description
DRUG	MEDI-522	MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. \[As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.\]

Timeline

• Start date: 2001-03-01
• Primary completion: 2002-04-01
• Completion: 2002-06-01
• First posted: 2005-12-09
• Last updated: 2009-01-29

Locations

1 site across 1 country: France